1ISG-001 Analysis of the use of oral oncology targeted therapies in a region of Spain

• Published in: European journal of hospital pharmacy. Science and practice 2024-03, Vol.31 (Suppl 1), p.A6-A7
• Main Authors: Rosas Espinoza, C, Alonso Castro, V, Maroto García, E, García Cerezuela, MD, Santos Mena, B, Nieves Sedano, M, Gómez Caballero, EP, Jiménez Moreno, P, Alioto, D, López Centeno, B, Calvo Alcántara, MJ
• Format: Article
• Language: English
• Subjects: Clinical medicine; Conflicts of interest; Drugs; Economic impact; Expenditures; Mutation; Oncology; Pharmaceuticals; Section 1: Introductory statements and governance
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2024-eahp.13

Background and ImportanceIndividualised treatments are the most important oncology pharmacotherapeutic innovation nowadays. The high cost of such treatments may hinder their incorporation into clinical practice.Aim and ObjectivesTo analyse the impact of the incorporation of oral oncology targeted therapies (OOTT) into routine clinical practice in a region.Material and MethodsRetrospective, descriptive study of the uptake and economic impact of OOTT between 2012 and 2022.Analysis of incorporation and economic impact included OOTT for six molecular targets, which were dispensed in Hospital Pharmacy Services. ALK/ROS1 mutations were analysed together because the indication of OOTT could not be identified.Regional consumption registers were used as a source of data.ResultsAvailable OOTT options increased by 500%, with 18 authorised drugs at the end of the study. In 2012–2013, only ALK/ROS1 and EGFR drugs were available. BRAF and MEK drugs were added in 2014 and BRCA drugs in 2015.The percentage of treatments used (greater than 10%) by mutation are shown in table 1.Abstract 1ISG-001 Table 1 Mutation Beginning of the study End of the study ALK/ROS1 Crizotinib (100%) Alectinib (44%), lorlatinib (26%), crizotinib (15%) EGFR Erlotinib (100%) Osimertinib (84%), afatinib (7%), erlotinib (6%) BRAF Vemurafenib (72%), dabrafenib (28%) Dabrafenib (54%), encorafenib (41%) MEK Trametinib (100%) Trametinib (60%), binimetinib (38%) BRCA Olaparib (100%) Niraparib (49%), olaparib (47%) In 2012, EGFR drugs had the greatest impact on both treated patients (99.8%) and pharmaceutical expenditure (100%). In 2022, BRCA drugs had the greatest impact on treated patients (34%), while the highest pharmaceutical expenditure (34%) was still on EGFR drugs.By the end of the study, OOTT treatments had increased by 179% and pharmaceutical expenditure by 494%. Drug distribution by mutation was 34% BRCA, 28% EGFR, 15% ALK/ROS1, 13% BRAF, and 11% MEK. The economic impact was 108,138,186€ accumulated over the entire study period.Conclusion and RelevanceTargeted therapies have had a relevant impact in recent years, with new drugs and diagnostic techniques increasing the eligible population. Stringent evaluation and adequate selection of these drugs are necessary in order to optimise the incorporation of innovative therapies while guaranteeing the sustainability of the public healthcare system in Spain.References and/or AcknowledgementsConflict of InterestNo conflict of interest.